Physician profile
Joseph C Caperna
NPI 1720141153
$8,257.51
in general payments reported to CMS, 2019-2025
14 companies · $1,373 in 2025
The $1,373 reported for 2025 was more than what 82% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $127 · 2021: $1,535 · 2022: $1,596 · 2023: $1,703 · 2024: $1,594 · 2025: $1,373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,609 · Travel and Lodging: $50.47 · Education: $10.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,608.75 |
| Travel and Lodging | $50.47 |
| Education | $10.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,440.57 | 2020-2025 | Descovy, Biktarvy |
| Viiv Healthcare Company | $2,770.03 | 2019-2025 | Dovato, Rukobia, Cabenuva |
| Janssen Biotech, INC. | $926.09 | 2019-2023 | Symtuza |
| Emd Serono, INC. | $376.38 | 2021-2025 | Serostim, Serostim |
| Janssen Products, LP | $303.89 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $139.74 | 2023-2024 | |
| Glaxosmithkline, LLC. | $74.56 | 2020-2022 | |
| Abbvie INC. | $62.81 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $40.86 | 2025 | |
| Janssen Pharmaceuticals, INC | $39.22 | 2021-2023 | |
| Theratechnologies INC. | $24.62 | 2024 | Egrifta, Trogarzo |
| Tolmar, INC. | $21.48 | 2025 | Jatenzo |
| Novo Nordisk INC | $20.54 | 2020 | |
| Allergan, INC. | $16.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Caperna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.